Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_assertion type Assertion NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_head.
- NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_assertion description "[The multivariate-adjusted odds ratios of developing HCC for those who had low and high serum levels of AFB1-albumin adducts compared with those who had a undetectable adduct level as the referent (odds ratio = 1.0) were 4.1 and 12.4, respectively, for HBsAg carriers with null GST M1 genotype (P < .01, on the basis of the significance test for trend); 0.7 and 1.4 for those with non-null GST Ml genotype (P = .98); 1.8 and 10.2 for those with null GST T1 genotype (P < .05); and 1.3 and 0.8 for those with non-null GST T1 genotype (P = .93).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_provenance.
- NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_assertion evidence source_evidence_literature NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_provenance.
- NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_assertion SIO_000772 8659516 NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_provenance.
- NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_assertion wasDerivedFrom befree-2016 NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_provenance.
- NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_assertion wasGeneratedBy ECO_0000203 NP1351610.RAoB4Fg9A68MNPQfNMvYcAPgMipwxKBrGvF-_n3INMPyA130_provenance.